Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00793793
Other study ID # 1220.2
Secondary ID 2007-001158-19
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2007
Est. completion date January 25, 2011

Study information

Verified date August 2018
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate safety, antiviral activity, and pharmacokinetics of BI 201335 NA in HCV genotype 1 infected patients treated for 14 days monotherapy followed by BI 201335 NA combination therapy with PegIFN/RBV for an additional 14 days for treatment-naïve patients; or for 28 days as BI 201335 NA combination therapy with PegIFN/RBV for treatment-experienced patients.

A secondary objective is to investigate antiviral activity, potential drug-drug interactions and safety of combination therapy of BI 201335 NA and PegIFN/RBV up to 28 days for treatment-naïve patients.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date January 25, 2011
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

1a. For treatment-naïve patients: no prior therapy with interferon, peginterferon, or ribavirin for acute or chronic hepatitis C infection

1b. For treatment-experienced patients: confirmed virological failure during or after combination treatment with an approved dose of alfa-2a or alfa-2b peginterferon combined with ribavirin; such patients must have received at least 12 weeks of therapy with a 90 day washout period prior to screening and must have documentation of medical history prior to enrolment in 1220.2 2. Age 18 years or older 3. Signed informed consent form prior to trial participation 4. Male or female with documented hysterectomy or menopausal female with last menstrual period at least 6 months prior to screening 5. Chronic hepatitis C infection of genotype 1, diagnosed by positive HCV serology test (HCV Ab positive) or detectable HCV RNA at least 6 months prior to screening 6. HCV viral load >= 100,000 IU/mL at screening 7. TSH and T4 within normal limits or adequately controlled thyroid function 8. Histological evidence within 36 months prior to study enrolment of any degree of chronic necroinflammatory activity or the presence of fibrosis (Ishak Grade 1-4 or Metavir Grade 1-3)

Exclusion criteria:

1. Patients who have been previously treated with at least one dose of any protease inhibitor for acute or chronic hepatitis C infection

2. Evidence of liver disease due to causes other than chronic HCV infection

3. Positive ELISA for HIV-1 or HIV-2

4. Hepatitis B virus (HBV) infection based on presence of Hbs Ag or HBV DNA

5. Any previous liver biopsy consistent with cirrhosis

6. Decompensated liver diseases as evidenced by ascites, portal hypertension, jaundice or hepatic encephalopathy

7. Haemophilia

8. Hemoglobinopathy (e.g., thalassemia major or sickle cell anemia)

9. Severe pre-existing psychiatric disease

10. Poorly controlled diabetes mellitus

11. Ischaemic heart disease

12. Chronic obstructive airway disease

13. Autoimmune disease; including autoimmune hepatitis

14. History of alcohol abuse within the past 12 months

15. Hyperbilirubinemia (conjugated bilirubin) >1.5x ULN

16. Alkaline phosphatase >1.5x ULN

17. ALT and AST levels >= 5 x ULN

18. Hemoglobin < 12.0 g/dL for women and < 13.0 g/dL for men

19. White blood cell count < 2000 cells/mm3

20. Absolute Neutrophil Count < 1500 cells/mm3

21. Platelet count < 100,000 cells/mm3

22. Prothrombin time INR (Institutional Normalized Ratio) prolonged to > 1.5 x ULN

23. Usage of any investigational drug within 30 days prior to enrolment; or the planned usage of an investigational drug during the course of the current study

24. Known hypersensitivity to study drugs

Study Design


Intervention

Drug:
BI201335
patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
BI201335
patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
BI201335
patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
BI201335
patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
Placebo


Locations

Country Name City State
France 1220.2.3304A Boehringer Ingelheim Investigational Site Lyon
France 1220.2.3303A Boehringer Ingelheim Investigational Site Marseille
France 1220.2.3301A Boehringer Ingelheim Investigational Site Paris
France 1220.2.3302A Boehringer Ingelheim Investigational Site Paris
Germany 1220.2.49002 Boehringer Ingelheim Investigational Site Berlin
Germany 1220.2.49005 Boehringer Ingelheim Investigational Site Düsseldorf
Germany 1220.2.49006 Boehringer Ingelheim Investigational Site Hannover
Germany 1220.2.49004 Boehringer Ingelheim Investigational Site Kiel
Germany 1220.2.49003 Boehringer Ingelheim Investigational Site Mainz
Spain 1220.2.34001 Boehringer Ingelheim Investigational Site Madrid
United States 1220.2.14 Boehringer Ingelheim Investigational Site Austin Texas
United States 1220.2.17 Boehringer Ingelheim Investigational Site Baltimore Maryland
United States 1220.2.11 Boehringer Ingelheim Investigational Site New York New York
United States 1220.2.12 Boehringer Ingelheim Investigational Site New York New York
United States 1220.2.10 Boehringer Ingelheim Investigational Site San Francisco California
United States 1220.2.15 Boehringer Ingelheim Investigational Site San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  France,  Germany,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy: VR (Virologic Response) of >=2 log10 Reduction in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Any Time up to Day 14 (naïve Patients) or Day 28 (Experienced Patients) Efficacy endpoint: VR (virologic response) of >=2 log10 reduction in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) from baseline at any time up to Day 14 (naïve patients) or Day 28 (experienced patients). Baseline and up to 4 weeks
Primary Occurrence of Adverse Events (AEs) During BI201335 + Washout Period Occurrence of Adverse Events (AEs) during BI201335 + washout period. For placebo patients include all AEs through 30 days after trial discontinuation. from day 1 and up to 4 weeks + 4 days washout
Primary Occurrence of Serious Adverse Events (SAEs) During BI201335 + Washout Period Occurrence of Serious Adverse Events (SAEs)during BI201335 or BI201335+ washout period. For placebo patients include all SAEs through 30 days after trial discontinuation. from day 1 and up to 4 weeks + 4 days washout
Primary Occurrence of Laboratory Test Abnormalities and With Respect to Division of AIDS (DAIDS) Classification and Laboratory Test Values Change Over Time Occurrence of laboratory test abnormalities and with respect to Division of AIDS (DAIDS) classification and laboratory test values change over time.
ALT=Alanine transaminase (SGPT), AST=Aspartate transaminase (SGOT).
Baseline and up to 4 weeks
Secondary Maximum Viral Load Reduction From Baseline up to Day 14 for Treatment-naïve Patients and Day 28 Treatment for Treatment-experienced Patients Maximum viral load reduction from baseline up to Day 14 for treatment-naïve patients and Day 28 treatment for treatment-experienced patients. Baseline and up to 4 weeks
Secondary Change From Baseline in Viral Load on Day 14 for Treatment-naïve Patients and on Day 28 Treatment for Treatment-experienced Patients Change from baseline in viral load on Day 14 for treatment-naïve patients and on Day 28 treatment for treatment-experienced patients. Baseline and up to 4 weeks
Secondary Rapid Virologic Response (RVR) Rapid virologic response (RVR): Plasma HCV RNA level below the limit of detection of the Roche COBAS Taqman HCV/HPS assay (10 IU/mL) on Day 28 for all patients. week 4
Secondary Early Virologic Response (EVR) Early Virologic Response (EVR): >=2 log10 reduction in plasma HCV RNA level from baseline at week 12 (day 84) week 12
Secondary Complete EVR1 (cEVR1) VL (Viral load) below the limit of quantification of the Roche COBAS Taqman HCV/HPS assay (25 IU/mL) at 4 weeks and below the limit of detection of the Roche COBAS Taqman HCV/HPS assay (10 IU/mL) at 12 weeks week 4 and week 12
Secondary Complete EVR2 (cEVR2) VL below the limit of detection at both 4 weeks and 12 weeks week 4 and week 12
Secondary End of Treatment Response (ETR) End of Treatment Response (ETR): Plasma HCV RNA level below the limit of detection of the Roche COBAS Taqman HCV/HPS assay (10 IU/mL) at week 48 (Day 336). week 48
Secondary Sustained Virologic Response (SVR) Sustained Virologic Response (SVR): Plasma HCV RNA level below the limit of detection of the Roche COBAS Taqman HCV/HPS assay (10 IU/mL) at week 72 (Day 504). week 72
Secondary Achievement of an HCV RNA Level Below the Limit of Detection Over Time Achievement of an HCV RNA level below the limit of detection of the Roche COBAS Taqman HCV/HPS assay (10 IU/mL) over time from day 1 and up to 4 weeks
Secondary Achievement of an HCV RNA Level Below the Limit of Quantification Over Time Achievement of an HCV RNA Level Below the Limit of quantification of the Roche COBAS Taqman HCV/HPS assay (25 IU/mL) Over Time from day 1 and up to 4 weeks
Secondary Achievement of a >= 2 log10 Reduction in Plasma HCV RNA Level From Baseline Over Time Achievement of a >= 2 log10 reduction in plasma HCV RNA level from baseline over time. from day 1 and up to 4 weeks
Secondary Occurrence of AEs, by Action Taken With Regard to Study Medication Occurrence of AEs, by action taken with regard to study medication. from day 1 and up to 4 weeks
Secondary Occurrence of Discontinuations Due to AEs During BI201335 or BI201335+PegIFN/RBV Combination Treatment Period Occurrence of discontinuations due to AEs during BI201335 or BI201335+PegIFN/RBV combination treatment period. from day 1 and up to 4 weeks
Secondary PK (Pharmacokinetic) Parameter After the First Dose: Cmax ( Maximum Measured Concentration of the Analyte in Plasma) PK (pharmacokinetic) parameter after the first dose: Cmax ( Maximum measured concentration of the analyte in plasma ). Times of -0:15, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, and 16:00 h relative to first administration of trial medication (on day 1)
Secondary PK Parameter After the First Dose: Tmax (Time From (Last) Dosing to the Maximum Measured Concentration of the Analyte in Plasma) PK parameter after the first dose: tmax (Time from (last) dosing to the maximum measured concentration of the analyte in plasma). Times of -0:15, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, and 16:00 h relative to first administration of trial medication (on day 1)
Secondary PK Parameter After the First Dose: AUCt,1 (Area Under the Concentration-time Curve of the Analyte in Plasma Over a Uniform Dosing Interval t on Day 1) PK parameter after the first dose: AUCt,1 (Area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t on day 1). Times of -0:15, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, and 16:00 h relative to first administration of trial medication (on day 1)
Secondary PK Parameter at Steady State After the Last Dose: Cmax,ss (Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t) PK parameter at steady state after the last dose: Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t). Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter at Steady State After the Last Dose: Tmax,ss (Time From Last Dosing to the Maximum Measured Concentration of the Analyte in Plasma at Steady State ) PK parameter at steady state after the last dose: tmax,ss (Time from last dosing to the maximum measured concentration of the analyte in plasma at steady state ). Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter at Steady State After the Last Dose: Cmin,ss (Minimum Measured Concentration of the Analyte in Plasma) PK parameter at steady state after the last dose: Cmin,ss (Minimum measured concentration of the analyte in plasma). Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter at Steady State After the Last Dose: AUCt,ss (Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t) PK parameter at steady state after the last dose: AUCt,ss ((Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t). Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter at Steady State After the Last Dose: t1/2,ss (Terminal Half-life of the Analyte in Plasma at Steady State ) PK parameter at steady state after the last dose: t1/2,ss (Terminal half-life of the analyte in plasma at steady state [h] ) Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter at Steady State After the Last Dose: MRTpo,ss (Mean Residence Time of the Analyte in the Body at Steady State After Oral Administration) PK parameter at steady state after the last dose: MRTpo,ss (Mean residence time of the analyte in the body at steady state after oral administration [h] ) Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter at Steady State After the Last Dose: CL/F,ss (Apparent Clearance of the Analyte in Plasma at Steady State Following Multiple Oral Dose Administration ) PK parameter at steady state after the last dose (if applicable): CL/F,ss (ss Apparent clearance of the analyte in plasma at steady state following multiple oral dose administration [mL/min] ) Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter at Steady State After the Last Dose: Vz/F,ss (Apparent Volume of Distribution During the Terminal Phase z at Steady State Following an Oral Administration ) PK parameter at steady state after the last dose: Vz/F,ss (Apparent volume of distribution during the terminal phase z at steady state following an oral administration [L] ) Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to last administration of trial medication (on day 28)
Secondary PK Parameter for Drug-drug Interaction (naïve Patients With =1 Log Reduction on Day 10): AUCt,ss (Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t ) PK parameter for drug-drug interaction (naïve patients with =1 log reduction on Day 10): AUCt,ss ( Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t ). Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to administration of trial medication in the morning of Day 14 (on day 14)
Secondary PK Parameter for Drug-drug Interaction (naïve Patients With =1 Log Reduction on Day 10): Cmax,ss PK parameter for drug-drug interaction (naïve patients with =1 log reduction on Day 10): Cmax,ss. Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to administration of trial medication in the morning of Day 14 (on day 14)
Secondary PK Parameter for Drug-drug Interaction (naïve Patients With =1 Log Reduction on Day 10): Cmin, ss PK parameter for drug-drug interaction (naïve patients with =1 log reduction on Day 10): Cmin, ss. Times of -0:05, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00. 8:00. 12:00, 16:00, 24:00 h relative to administration of trial medication in the morning of Day 14 (on day 14)
Secondary Accumulation Ratio of the Analyte in Plasma Following Multiple Doses Over a Uniform Dosing Interval: RAcmax For TN patients, comparing exposure on Day 14 to the first dose on Day 1; for TE patients, comparing exposure on Day 28 to the first dose on Day 1. Day 1, Day 14, and Day 28
Secondary Accumulation Ratio of the Analyte in Plasma Following Multiple Doses Over a Uniform Dosing Interval: RAauc For TN patients, comparing exposure on Day 14 to the first dose on Day 1; for TE patients, comparing exposure on Day 28 to the first dose on Day 1. Day 1, Day 14, and Day 28
See also
  Status Clinical Trial Phase
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03740906 - Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
Terminated NCT02465203 - 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study Phase 3
Completed NCT02262728 - An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease Phase 2
Completed NCT01429792 - A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) Phase 4
Completed NCT02541409 - Directly Observed Therapy for HCV in Chennai, India Phase 2
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Withdrawn NCT01608737 - A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection Phase 3
Completed NCT02113631 - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir N/A
Completed NCT01435044 - Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection Phase 2
Completed NCT01435226 - GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection Phase 2
Completed NCT01399619 - Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4) Phase 3
Completed NCT01447446 - An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C N/A
Terminated NCT01168856 - An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens N/A
Completed NCT00725751 - Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) N/A
Completed NCT00377182 - A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection. Phase 2
Completed NCT00375661 - Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC Phase 4
Completed NCT00217139 - A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection Phase 2
Completed NCT00723632 - Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) N/A
Completed NCT00704717 - Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) N/A

External Links